DOI:

10.37988/1811-153X_2024_4_40

Comparative characteristics of formulations for the symptomatic treatment of xerostomia

Downloads

Authors

  • O.E. Shishkina 1, PhD in Medical Sciences, associate professor of the Oral and maxillofacial surgery Department, director of the Institute of Dentistry
    ORCID: 0009-0000-0711-309X
  • V.M. Vorobyeva 1, PhD in Pharmacy, associate professor of the Biological chemistry, clinical laboratory diagnostics Department
    ORCID: 0009-0009-0028-7076
  • O.N. Mazko 1, PhD in Biology, associate professor of the Pharmacology Department
    ORCID: 0000-0001-7299-4516
  • N.V. Semennikova 1, PhD in Medical Sciences, associate professor of the Oral and maxillofacial surgery Department
    ORCID: 0000-0003-0290-8760
  • E.A. Berent 1, 4th year student at the Institute of Dentistry
    ORCID: 0009-0009-8502-6309
  • K.S. Loor 1, resident at the Institute of Pharmacy
  • 1 Altai State Medical University, 656038, Barnaul, Russia

Abstract

The use of saliva substitutes is a key concept in the treatment of xerostomia, aimed at reducing the symptoms of dry mouth and maintaining oral health. Based on reference data and scientific literature, an analysis of the available products for replacement therapy for xerostomia and their main ingredients was carried out. The characteristics of the main components of salivary protectors are given, taking into account their functions in the composition of gels and sprays for the symptomatic therapy of xerostomia: electrolyte salts, enzymes, mucin, hydrocolloid polymers, water-retaining polyhydric alcohols, sugar substitutes, and herbal preparations. The limited availability of dental products on the market — salivary substitutes, mainly of foreign manufacture, especially in conditions of economic isolation, taking into account the growth of this pathology, determines the relevance of developing domestic products for the treatment of xerostomia. The necessity of developing salivary substitutes is substantiated in connection with the prevalence of this syndrome, the tendency to increase due to demographic aging of the population and the need to take xerogenic drugs for the treatment of systemic diseases.

Key words:

xerostomia, hyposalivation, dry mouth, artificial saliva, salivary substitutes, mucin, polymer hydrocolloids

For Citation

[1]
Shishkina O.E., Vorobyeva V.M., Mazko O.N., Semennikova N.V., Berent E.A., Loor K.S. Comparative characteristics of formulations for the symptomatic treatment of xerostomia. Clinical Dentistry (Russia).  2024; 27 (4): 40—53. DOI: 10.37988/1811-153X_2024_4_40

References

  1. Antonova I.N., et al. Clinical features of the manifestation of xerostomia. The Dental Institute. 2021; 2 (91): 92—93 (In Russian). eLIBRARY ID: 46227987
  2. Arakelyan M.G., Tambovtseva N.V., Arzukanyan A.V. The main causes and clinical manifestations of xerostomia. Russian Journal of Dentistry. 2016; 2: 74—78 (In Russian). eLIBRARY ID: 26040390
  3. Afanasyev V.V., Sirota N.A., Vinokurov N.S. Features of the psycho-emotional state of patients suffering from xerostomia. Bulletin of Kyrgyz State Medical Academy. 2022; 2: 42—44 (In Russian). eLIBRARY ID: 49166366
  4. Grigoriev S.S., et al. Dry mouth syndrome (literature review). Ural Medical Journal. 2019; 12 (180): 18—25 (In Russian). eLIBRARY ID: 41468231
  5. Łysik D., et al. Artificial saliva: challenges and future perspectives for the treatment of xerostomia. Int J Mol Sci. 2019; 20 (13): 3199. PMID: 31261876
  6. Kapourani A., et al. A review on xerostomia and its various management strategies: The role of advanced polymeric materials in the treatment approaches. Polymers (Basel). 2022; 14 (5): 850. PMID: 35267672
  7. Izrailov A.M., Antonova I.N. Modern approaches to the diagnosis of xerostomia. Parodontologiya. 2023; 3: 235—246 (In Russian). eLIBRARY ID: 54673321
  8. Pedersen A., et al. Salivary functions in mastication, taste and textural perception, swallowing and initial digestion. Oral Dis. 2018; 24 (8): 1399—1416. PMID: 29645367
  9. Morozova S.V., Meytel I.Y. Xerostomia: reasons and methods of correction. Medical Council. 2016; 18: 124—127 (In Russian). eLIBRARY ID: 27474988
  10. Dreyer N.S., et al. [Xerostomia]. Ugeskr Laeger. 2021; 183 (27): V11200814 (In Danish). PMID: 34219641
  11. Izrailov A.M., Antonova I.N. Efficiency of topical use of hyaluronic acid preparations in patients with various etiology xerostomia. The Dental Institute. 2023; 3 (100): 74—76 (In Russian). eLIBRARY ID: 54503741
  12. Nascimento M.L., et al. Impact of xerostomia on the quality of life of patients submitted to head and neck radiotherapy. Med Oral Patol Oral Cir Bucal. 2019; 24 (6): e770-e775. PMID: 31655838
  13. Ouanounou A. Xerostomia in the geriatric patient: Causes, oral manifestations, and treatment. Compend Contin Educ Dent. 2016; 37 (5): 306—311; quiz312. PMID: 27213776
  14. Agostini B.A., et al. How common is dry mouth? Systematic review and meta-regression analysis of prevalence estimates. Braz Dent J. 2018; 29 (6): 606—618. PMID: 30517485
  15. Pina G.M.S., et al. Prevalence of hyposalivation in older people: A systematic review and meta-analysis. Gerodontology. 2020; 37 (4): 317—331. PMID: 32965067
  16. Makeeva I.M., Arakelyan M.G., Doroshina V.Yu., Polyakova M.A., Margaryan E.G., Arzukanyan A.V. Application of oral Foams Splat Oral Care Foam 2 in 1 in patients with false xerostomia. Stomatology. 2018; 6: 45—48 (In Russian). eLIBRARY ID: 36647242
  17. Teoh C.X.W., Thng M., Lau S., Taing M.W., Chaw S.Y., Siskind D., Kisely S. Dry mouth effects from drugs used for depression, anxiety, schizophrenia and bipolar mood disorder in adults: systematic review. BJPsych Open. 2023; 9 (2): e53. PMID: 36938801
  18. Yousefi H., Abdollahi M. An update on drug-induced oral reactions. J Pharm Pharm Sci. 2018; 21 (1): 171—183. PMID: 29789102
  19. Derkacheva E.I., Ron G.I. The clinical manifestation in the oral cavity xerostomia different etiology. Ural Medical Journal. 2014; 5 (119): 44—47 (In Russian). eLIBRARY ID: 21982443
  20. Belenova I.A., et al. Xerostomia as an idiopathic symptom in dentistry. Applied and IT Research in Medicine. 2023; 1: 36—41 (In Russian). eLIBRARY ID: 50496645
  21. Wolff A., et al. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: A systematic review sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017; 17 (1): 1—28. PMID: 27853957
  22. Tanasiewicz M., Hildebrandt T., Obersztyn I. Xerostomia of various etiologies: A review of the literature. Adv Clin Exp Med. 2016; 25 (1): 199—206. PMID: 26935515
  23. Kontogiannopoulos K.N., et al. A review of the role of natural products as treatment approaches for xerostomia. Pharmaceuticals (Basel). 2023; 16 (8): 1136. PMID: 37631049
  24. Alhejoury H.A., et al. Artificial saliva for therapeutic management of xerostomia: A narrative review. J Pharm Bioallied Sci. 2021; 13 (Suppl 2): S903-S907. PMID: 35017895
  25. Hu J., Andablo-Reyes E., Mighell A., Pavitt S., Sarkar A. Dry mouth diagnosis and saliva substitutes-A review from a textural perspective. J Texture Stud. 2021; 52 (2): 141—156. PMID: 33274753
  26. Epstein J.B., Beier Jensen S. Management of hyposalivation and xerostomia: Criteria for treatment strategies. Compend Contin Educ Dent. 2015; 36 (8): 600—3. PMID: 26355444
  27. Gil-Montoya J.A., et al. Treatment of xerostomia and hyposalivation in the elderly: A systematic review. Med Oral Patol Oral Cir Bucal. 2016; 21 (3): e355—66. PMID: 27031061
  28. Khavandgar Z., et al. Evaluation and management of dry mouth and its complications in rheumatology practice. Expert Rev Clin Immunol. 2024; 20 (1): 1—19. PMID: 37823475
  29. Afanasiev V.V., Vinokurov N.S. The results of using xerostom mouthwash in complex treatment of patients with xerostomia. Russian Journal of Dentistry. 2020; 5: 318—320 (In Russian). eLIBRARY ID: 45156419
  30. Roblegg E., et al. Saliva: An all-rounder of our body. Eur J Pharm Biopharm. 2019; 142: 133—141. PMID: 31220573
  31. Canon F., et al. Saliva and flavor perception: perspectives. J Agric Food Chem. 2018; 66 (30): 7873—7879. PMID: 29962207
  32. Salum F.G., Medella-Junior F.A.C., Figueiredo M.A.Z., Cherubini K. Salivary hypofunction: An update on therapeutic strategies. Gerodontology. 2018; 35 (4): 305—316. PMID: 29956369
  33. Villa A., Connell C.L., Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag. 2015; 11: 45—51. PMID: 25653532
  34. Assery M.K.A. Efficacy of artificial salivary substitutes in treatment of xerostomia: A systematic review. J Pharm Bioallied Sci. 2019; 11 (Suppl 1): S1-S12. PMID: 30923424
  35. Vinke J., Kaper H.J., Vissink A., Sharma P.K. An ex vivo salivary lubrication system to mimic xerostomic conditions and to predict the lubricating properties of xerostomia relieving agents. Sci Rep. 2018; 8 (1): 9087. PMID: 29904095
  36. Nayak P.A., et al. The effect of xylitol on dental caries and oral flora. Clin Cosmet Investig Dent. 2014; 6: 89—94. PMID: 25422590
  37. Vavilova T.P., Derkacheva N.I., Ostrovskaya I.G. Antimicrobial peptides — the multifunctional protection of the tissues of the oral cavity. Russian Stomatology. 2015; 3: 3—12 (In Russian). eLIBRARY ID: 25308580
  38. Volosova E.V., et al. Problems of diagnostics and treatment of xerostomia. Current view. Medical alphabet. 2020; 35: 44—47 (In Russian). eLIBRARY ID: 44560472
  39. Derkacheva E.I., Ron G.I., Kaminskaya L.A. The influence of the drug SALIVA+ on the quality of life of patients with xerostomia on the background of antihypertensive therapy. Ural Medical Journal. 2015; 6 (129): 44—47 (In Russian). eLIBRARY ID: 24323391
  40. Khurshid Z., et al. Histatin peptides: Pharmacological functions and their applications in dentistry. Saudi Pharm J. 2017; 25 (1): 25—31. PMID: 28223859
  41. Marimuthu D., Han K.M., Mohamad M.S.F., Azman M. Saliva substitute mouthwash in nasopharyngeal cancer survivors with xerostomia: a randomized controlled trial. Clin Oral Investig. 2021; 25 (5): 3105—3115. PMID: 33175253
  42. Hoffmann W. Salivary trefoil factor family (TFF) peptides and their roles in oral and esophageal protection: Therapeutic potential. Int J Mol Sci. 2021; 22 (22): 12221. PMID: 34830103
  43. Chaudhury N.M., Proctor G.B., Karlsson N.G., Carpenter G.H., Flowers S.A. Reduced Mucin-7 (Muc7) sialylation and altered saliva rheology in Sjögren’s syndrome associated oral dryness. Mol Cell Proteomics. 2016; 15 (3): 1048—59. PMID: 26631508
  44. Ployon S., et al. The membrane-associated MUC1 improves adhesion of salivary MUC5B on buccal cells. Application to development of an in vitro cellular model of oral epithelium. Arch Oral Biol. 2016; 61: 149—55. PMID: 26580166
  45. Faruque M., et al. A review on the role of salivary MUC5B in oral health. J Oral Biosci. 2022; 64 (4): 392—399. PMID: 36206992
  46. Huang L.T., et al. Recombinant production of glycoengineered mucins in HEK293-F Cells. Methods Mol Biol. 2024; 2763: 281—308. PMID: 38347419
  47. Shurer C.R., et al. Stable recombinant production of codon-scrambled lubricin and mucin in human cells. Biotechnol Bioeng. 2019; 116 (6): 1292—1303. PMID: 30684357
  48. Park S., et al. Recombinant mucin biotechnology and engineering. Adv Drug Deliv Rev. 2023; 193: 114618. PMID: 36375719
  49. Porangaba L.P., et al. Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region. Curr Oncol. 2024; 31 (2): 1102—1112. PMID: 38392076
  50. Ghosh S., Iacucci M. Diverse immune effects of bovine colostrum and benefits in human health and disease. Nutrients. 2021; 13 (11): 3798. PMID: 34836054
  51. Hamman H., Steenekamp J., Hamman J. Use of natural gums and mucilages as pharmaceutical excipients. Curr Pharm Des. 2015; 21 (33): 4775—97. PMID: 26290212
  52. Molchanova Y.N., Trubnikov A.A., Onegin S.V. Comparative characteristics of dental gels compositions are presented in the local pharmaceutical market. Ural Medical Journal. 2018; 7 (162): 10—14 (In Russian). eLIBRARY ID: 36367336
  53. Lipatov V.A., et al. Application of cellulose derivatives in experimental surgery of parenchymal organs. Eruditio Juvenium. 2020; 2: 269—283 (In Russian). eLIBRARY ID: 43043488
  54. Semenova E.V., et al. The use of seaweed in medicine and pharmacy. Modern Problems of Science and Education. 2019; 6: 186 (In Russian). eLIBRARY ID: 42406053
  55. Zakharova V.A., Fidorovskaya Y.S., Khlystova T.S., Kildeeva N.R. Alginic acid derivatives: structural features, properties and prospects for medicine use. Industrial processes and technologies. 2022; 5: 64—79 (In Russian). eLIBRARY ID: 50009588
  56. Sashkina T.I., et al. Assessment of data on the current application of hyaluronic acid in dentistry. Possible complications. Kremlin Medicine Journal. 2023; 4: 73—77 (In Russian). eLIBRARY ID: 59554986
  57. Furness S., et al. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011; CD008934. PMID: 22161442
  58. Moriconi E., et al. Neuroendocrine and metabolic effects of low-calorie and non-calorie sweeteners. Front Endocrinol (Lausanne). 2020; 11: 444. PMID: 32765425
  59. Salom M., et al. Efficacy and safety of a new oral saliva equivalent in the management of xerostomia: a national, multicenter, randomized study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119 (3): 301—9. PMID: 25617119
  60. Skrinjar I., et al. Comparison between three different saliva substitutes in patients with hyposalivation. Clin Oral Investig. 2015; 19 (3): 753—7. PMID: 25617026
  61. Debras C., et al. Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study. PLoS Med. 2022; 19 (3): e1003950. PMID: 35324894
  62. Sinjari B., et al. Artificial saliva in diabetic xerostomia (ASDIX): Double blind trial of Aldiamed® versus placebo. J Clin Med. 2020; 9 (7): 2196. PMID: 32664567
  63. Alpöz E., et al. Impact of Buccotherm® on xerostomia: a single blind study. Spec Care Dentist. 2015; 35 (1): 1—7. PMID: 24835826
  64. Liang Z., Maher P. Structural requirements for the neuroprotective and anti-inflammatory activities of the flavanone sterubin. Antioxidants (Basel). 2022; 11 (11): 2197. PMID: 36358569
  65. Ross S.M. Aloe vera — peppermint gel (Veramin): an effective treatment for mouth dryness among ICU patients. Holist Nurs Pract. 2020; 34 (2): 129—131. PMID: 32049698
  66. Atashi V., et al. The effects of Aloe vera — peppermint (Veramin) moisturizing gel on mouth dryness and oral health among patients hospitalized in intensive care units: A triple-blind randomized placebo-controlled trial. J Res Pharm Pract. 2018; 7 (2): 104—110. PMID: 30050964
  67. Morales-Bozo I., et al. Evaluation of the effectiveness of a chamomile (Matricaria chamomilla) and linseed (Linum usitatissimum) saliva substitute in the relief of xerostomia in elders. Gerodontology. 2017; 34 (1): 42—48. PMID: 26763612
  68. De Rossi S.S., et al. A phase II clinical trial of a natural formulation containing tea catechins for xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 118 (4): 447—454.e3. PMID: 25240992
  69. Ameri A., et al. Evaluation of efficacy of an herbal compound on dry mouth in patients with head and neck cancers: A randomized clinical trial. J Evid Based Complementary Altern Med. 2016; 21 (1): 30—3. PMID: 26137850

Downloads

Received

August 7, 2024

Accepted

October 31, 2024

Published on

December 17, 2024